inactivated split-virus influenza vaccine

ApprovedVaccine

inactivated split-virus influenza vaccine is one of 51 biologic programs targeting Bone Marrow Transplantation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone Marrow TransplantationActive, not recruiting

Bone Marrow TransplantationApproved

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Bone Marrow Transplantation

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

20 2

Neoral

Novartis

Phase 3

15 3

Cytosar

Teva

Phase 3

12 4

Fludara

Sanofi

Phase 3

4 5

Nipent

Pfizer

Phase 3

2 6

Idamycin

Pfizer

Phase 3

2 7

Novantrone

Pfizer

Phase 3

2 8

Jakafi

Incyte

Phase 3

1 9

Gleevec

Novartis

Phase 3

1 10

Zometa

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Marrow Transplantation1 trial

Influenza Vaccination in Bone Marrow Transplantation

Completed·TThe Cleveland Clinic·Phase 4·NCT00419224·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for inactivated split-virus influenza vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — inactivated split-virus influenza vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for inactivated split-virus influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: TThe Cleveland Clinic

inactivated split-virus influenza vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Marrow Transplantation1 trial

References

Drug Info

Quick Facts

Related News